Benzinga - by Lisa Levin, Benzinga Editor.
Gainers
- Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
- OpGen, Inc. (NASDAQ: OPGN) shares jumped 109% to $0.4201 after the company requested to withdraw its registration statement on Form S-1.
- Novo Integrated Sciences, Inc. (NASDAQ: NVOS) shares gained 66.3% to $0.3343 after the company announced it signed a One Billion Dollar Master Collateral Transfer Agreement with Blacksheep Trust for the purpose and general use of monetization for a period of up to 15 years.
- CF Acquisition Corp. VIII (NASDAQ: CFFE) gained 61% to $29.51.
- Femasys Inc. (NASDAQ: FEMY) surged 48% to $2.2650 after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.
- RVL Pharmaceuticals plc (NASDAQ: RVLP) shares climbed 35.7% to $0.1060.
- SeaStar Medical Holding Corporation (NASDAQ: ICU) gained 35% to $0.2528 after the company announced it was granted Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device for Cardiorenal Syndrome.
- Structure Therapeutics Inc. (NASDAQ: GPCR) shares climbed 31.6% to $49.30 after the company announced results from its Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290 and provided a program update.
- T2 Biosystems, Inc. (NASDAQ: TTOO) rose 26.6% to $0.2258.
- Starbox Group Holdings Ltd. (NASDAQ: STBX) surged 22.8% to $1.0252.
- Capstone Green Energy Corporation (NASDAQ: CGRN) gained 20% to $0.60.
- Evolve Transition Infrastructure LP (NYSE: SNMP) jumped 19% to $1.6312.
- Velo3D, Inc. (NYSE: VLD) jumped 18.8% to $1.4850.
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) gained 17.1% to $0.6150.
- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) gained 17% to $0.24. Brainstorm Cell Therapeutics recently announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.
- Tritium DCFC Limited (NASDAQ: DCFC) gained 16% to $0.3598.
- Better Therapeutics, Inc. (NASDAQ: BTTX) rose 13.2% to $0.3899. Better Therapeutics completed enrollment in real-world evidence program evaluating long-term effectiveness of AspyreRx in Type 2 Diabetes.
- Editas Medicine, Inc. (NASDAQ: EDIT) shares rose 12% to $7.75. Stifel upgraded Editas Medicine from Hold to Buy and raised the price target from $9 to $17.
- Century Aluminum Company (NASDAQ: CENX) gained 10% to $7.27.
- FingerMotion, Inc. (NASDAQ: FNGR) gained 9.3% to $6.29.
- Duolingo, Inc. (NASDAQ: DUOL) climbed 8.9% to $173.32 after UBS initiated coverage on the stock with a Buy rating and a $195 price target.
- Customers Bancorp, Inc. (NYSE: CUBI) gained 8.2% to $35.01. Raymond James initiated coverage on Customers Bancorp with a Strong Buy rating and announced a price target of $60.
- NIKE, Inc. (NYSE: NKE) shares climbed 7.3% to $96.22 after posting upbeat quarterly earnings.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- The Glimpse Group, Inc. (NASDAQ: VRAR) shares dipped 42.5% to $1.87 after the company reported a wider FY23 loss.
- Capricor Therapeutics, Inc. (NASDAQ: CAPR) fell 41.4% to $3.4090 after the company announced a $23 million registered direct offering.
- Color Star Technology Co., Ltd. (NASDAQ: ADD) shares declined 28% to $1.08.
- Vaccinex, Inc. (NASDAQ: VCNX) fell 25.8% to $1.12 after the company reported pricing of $9.6 million public offering.
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) dipped 23.8% to $0.5321 after the company reported pricing of $4.5 million public offering.
- EBET, Inc. (NASDAQ: EBET) fell 23.5% to $0.0396 after the company announced a 1-for-30 reverse stock split.
- Corcept Therapeutics Incorporated (NASDAQ: CORT) declined 21% to $26.07.
- Portage Biotech Inc. (NASDAQ: PRTG) fell 18.4% to $1.8599 after announcing a $6 million registered direct offering.
- Baudax Bio, Inc. (NASDAQ: BXRX) fell 16.2% to $0.3789. Baudax Bio shares gained over 50% on Thursday after the company announced it was granted orphan drug designation by the FDA for TI-168 for the treatment of Hemophilia A with inhibitors.
- Lifezone Metals Limited (NYSE: LZM) declined 15.7% to $13.05.
- Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) tumbled 15% to $13.29. JP Morgan maintained Syndax Pharmaceuticals with an Overweight and lowered the price target from $36 to $33.
- WaveDancer, Inc. (NASDAQ: WAVD) fell 13% to $0.2350.
- Nine Energy Service, Inc. (NYSE: NINE) fell 11.7% to $4.00.
- Ascent Solar Technologies, Inc. (NASDAQ: ASTI) declined 11.6% to $1.82.
- Opera Limited (NASDAQ: OPRA) fell 11.3% to $11.57 after the company announced the pricing of its underwritten secondary public offering of 6,876,506 ADSs to be sold by a pre-IPO shareholder at a public offering price of $12.25 per ADS.
- Greenfire Resources Ltd. (NYSE: GFR) declined 9.8% to $4.9605.
- Bionomics Limited (NASDAQ: BNOX) fell 8.3% to $3.09. Bionomics shares jumped 244% on Thursday after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
- Badger Meter, Inc. (NYSE: BMI) fell 6.7% to $145.13. Northcoast Research downgraded Badger Meter from Neutral to Sell.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.